Integra LifeSciences - IART Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" IART shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IART, but not buy additional shares or sell existing shares.
View IART analyst ratings or view top-rated stocks.

5 equities research analysts have issued 12-month price targets for Integra LifeSciences' shares. Their IART share price forecasts range from $48.00 to $75.00. On average, they anticipate the company's share price to reach $58.17 in the next twelve months. This suggests a possible upside of 7.7% from the stock's current price.
View analysts price targets for IART or view top-rated stocks among Wall Street analysts.

Integra LifeSciences' stock was trading at $56.07 at the beginning of 2023. Since then, IART shares have decreased by 3.6% and is now trading at $54.03.
View the best growth stocks for 2023 here.

Integra LifeSciences saw a drop in short interest in the month of February. As of February 28th, there was short interest totaling 4,770,000 shares, a drop of 12.2% from the February 13th total of 5,430,000 shares. Based on an average trading volume of 490,300 shares, the days-to-cover ratio is currently 9.7 days. Approximately 6.7% of the shares of the company are short sold.
View Integra LifeSciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our IART earnings forecast.

Integra LifeSciences Holdings Co. (NASDAQ:IART) issued its quarterly earnings results on Wednesday, February, 22nd. The life sciences company reported $0.94 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.01. The life sciences company had revenue of $398 million for the quarter, compared to analysts' expectations of $398.57 million. Integra LifeSciences had a net margin of 11.59% and a trailing twelve-month return on equity of 16.51%. The company's revenue for the quarter was down 1.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.84 earnings per share.

ETFs with the largest weight of Integra LifeSciences (NASDAQ:IART) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Fidelity Digital Health ETF (FDHT), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Health Care Equipment ETF (XHE), First Trust Health Care AlphaDEX Fund (FXH), First Trust Horizon Managed Volatility Small/Mid ETF (HSMV), Invesco Nasdaq Future Gen 200 ETF (QQQS) and iShares U.S. Medical Devices ETF (IHI).

Integra LifeSciences shares split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly minted shares were distributed to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Integra LifeSciences updated its FY23 earnings guidance on Wednesday, February, 22nd. The company provided earnings per share (EPS) guidance of $3.43-3.51 for the period, compared to the consensus earnings per share estimate of $3.53. The company issued revenue guidance of $1.602-1.620 billion, compared to the consensus revenue estimate of $1.62 billion.

173 employees have rated Integra LifeSciences Chief Executive Officer Peter J. Arduini on Glassdoor.com. Peter J. Arduini has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra LifeSciences investors own include Boeing (BA), NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Marvell Technology (MRVL), Alexion Pharmaceuticals (ALXN) and Abbott Laboratories (ABT).

Integra LifeSciences trades on the NASDAQ under the ticker symbol "IART."

Integra LifeSciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (3.47%), Cooke & Bieler LP (3.27%), Clearbridge Investments LLC (3.09%), Fuller & Thaler Asset Management Inc. (1.81%), Dimensional Fund Advisors LP (1.44%) and Geode Capital Management LLC (1.27%). Insiders that own company stock include Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Michael J Mcbreen, Raymond G Murphy, Richard E Caruso, Stuart Essig and Tru St Partnership, LP.
View institutional ownership trends.

Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IART stock can currently be purchased for approximately $54.03.

Integra LifeSciences (NASDAQ:IART) has a market capitalization of $4.41 billion and generates $1.56 billion in revenue each year. The life sciences company earns $180.55 million in net income (profit) each year or $2.16 on an earnings per share basis.

The company employs 3,722 workers across the globe.

Integra LifeSciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The official website for the company is www.integralife.com. The life sciences company can be reached via phone at (609) 275-0500, via email at ir@integralife.com, or via fax at 609-750-4277.